<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425411</url>
  </required_header>
  <id_info>
    <org_study_id>vals262626</org_study_id>
    <nct_id>NCT01425411</nct_id>
  </id_info>
  <brief_title>Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy</brief_title>
  <official_title>Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mustafa Kemal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mustafa Kemal University</source>
  <brief_summary>
    <textblock>
      The study hypothesis: Valsartan as an angiotensin II receptor blocker treatment has
      beneficial effects on both midwall mechanics and myocardial functions in hypertensive
      patients with Left ventricular hypertrophy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in midwall fractional shortening (mFS) and tissue Doppler systolic wave (Sm) measured by echocardiography at six months</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline in systolic and diastolic blood pressure at six months</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in left ventricular mass index measured by echocardiography at six months</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Hypertension</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>Valsartan treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
    <description>80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months</description>
    <arm_group_label>Valsartan treatment</arm_group_label>
    <other_name>Diovan 80 mg</other_name>
    <other_name>Diovan 160 mg</other_name>
    <other_name>Co-diovan 160/12,5 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hypertension with left ventricular hypertrophy

        Exclusion Criteria:

          -  clinical or laboratory evidence of secondary hypertension

          -  heart failure

          -  ischemic heart disease

          -  valvular heart disease

          -  arrhythmias

          -  peripheral vascular disease

          -  chronic obstructive pulmonary disease

          -  neurologic disorders

          -  diabetes mellitus

          -  renal dysfunction

          -  notable systemic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatih Yalcin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mustafa Kemal University: Turkey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mustafa Kemal University School of Medicine, Department of Cardiology</name>
      <address>
        <city>Antioch</city>
        <zip>31100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2011</study_first_posted>
  <last_update_submitted>August 29, 2011</last_update_submitted>
  <last_update_submitted_qc>August 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mustafa Kemal University</investigator_affiliation>
    <investigator_full_name>Nagehan Kucukler</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>left ventricular hypertrophy</keyword>
  <keyword>angiotensin receptor blocker</keyword>
  <keyword>midwall mechanics</keyword>
  <keyword>tissue Doppler imaging</keyword>
  <keyword>Hypertension with left ventricular hypertrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

